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Persistent infection from high-risk HPV types is necessary
forthedevelopmentofcervicalcancerandconstitutesamain
cause for a signiﬁcant proportion of cancers in other sites
of the female anogenital tract such as the vulva, the vagina,
and the anus [1]. Cervical cancer in particular being the
third most common cancer in women (with approximately
530,000 cases and 275,000 deaths per year) [2]i sa ni m p o r -
tant global health issue warranting intensive preventive
eﬀorts [3]. Secondary prevention through cervical cytology
screening has been eﬀective in reducing the incidence and
the mortality of the disease [4]. However, cervical cytology
has certain limitations one of which is poor reproducibility.
In the study by A. C. Barcelos et al. titled “Atypical squamous
cells of undetermined signiﬁcance: bethesda classiﬁcation and
association with human papillomavirus” which appears in
this special issue, observers would agree in the diagnosis of
ASCUS only in two out of three cases.
Secondary screening eﬀorts focus on the detection and
subsequent treatment of cervical intraepithelial neoplasia
(CIN). However, the sensitivity of cytology in the detection
of CIN has been questioned [5]. Obviously failure of this
mechanism might result in the development of cervical
cancer. HPV DNA testing emerged as a way to improve the
deﬁciencies of cytology [6]. The study by Barcelos et al.
[7] conﬁrmed that HPV DNA testing with Hybrid Capture
II (HCII) can be applied in the triage of ASCUS cytology.
InterestinglytheHCIIpositivityrateinthiscohortofASCUS
smears (22%) was lower than in the ALTS (55%) [8].
HCII,however,doesnotallowHPVtyping.CertainPCR-
based tests allow the identiﬁcation of the speciﬁc genotypes
responsiblefortheinfection,whichcouldhavefutureclinical
applications. One of the ﬁrst steps in PCR is DNA extraction.
The study by Chranioti et al. [9] compared the accuracy
of the method after manual and after automated DNA
extraction and found better results with the former.
Cell cycle biomarkers such as E6&7 mRNA testing and
P16INK4a are further tools that could be used in the pre-
vention of cervical cancer [10]. However, biomarkers could
also have prognostic value and inﬂuence management of
cervical (pre-)cancer. In the study by F. M. Abu Backer et al.
titled “Clinicopathological comparison of adenocarcinoma of
cervix and endometrium using cell cycle markers: P16ink4a,
P21waf1, and p27Kip1 on 132 Cancers” the expression
of two less studied proteins, p21WAF1 and p27Kip1 was
signiﬁcantly associated with lymph node invasion in cervical
adenocarcinoma.
Most HPV infections are transient without clinical sig-
niﬁcance. However, in a minority of women HPV will persist
and will initiate the neoplastic process. Epigenetic event such
as gene methylation might play a role in the selection of the
women who will progress to cancer. The study by A. Spathis
et al. titled “Promoter methylation of p16INK4A,h M L H 1 ,a n d
MGMT in liquid-based cervical cytology samples compared
withclinicopathologicalﬁndingsandHPVpresence”examined
themethylation-dependentinactivationoftumorsuppressor
genes connected with cell cycle regulation as p16INK4A
and DNA repair mechanisms as human MutL Homolog 1
(hMLH1) and O6-methylguanine DNA methyl transferase
(MGMT). Even though the accuracy of methylation was
found lower than traditional tests, epigenetic eﬀects are areas
of promising future research.2 Infectious Diseases in Obstetrics and Gynecology
The deﬁciencies of secondary prevention, such as the
need for suﬃcient infrastructure, which is absent in develop-
ing countries, the false negative results, the adverse eﬀects of
overtreatment on subsequent pregnancy outcome [11, 12],
as well as the psychological morbidity resulting from HPV
infection [13]h a v el e f tp l e n t yo fr o o mf o ri m p r o v e m e n t .
With the introduction of HPV vaccines a combination of
secondary with primary prevention is now possible [14, 15].
The article by K. Natunen et al. titled “Aspects of prophy-
lactic vaccination against cervical cancer and other human
papillomavirus-related cancers in developing countries”o u t -
lines certain issues that arise with respect to application of
the vaccine in the developing countries where the need for
cervical cancer prevention is the greatest. They suggest that
given the low coverage rates, vaccination of the males might
have to be considered in order to produce herd immunity.
They also argue that strategies for vaccine implementation
w o u l dh a v et ob es c h o o lb a s e dw i t hc o m m u n i t yo u t r e a c h
activities in regions where school attendance is low.
Progressintheelucidationofthemechanismsofcarcino-
genesis has led to the development of exciting technologies
thatcanbeusedforloweranogenitaltractcancerprevention.
The main challenge we face now is to ﬁnd the proper way to
use all these discoveries for the beneﬁt of women’s health.
George Koliopoulos
Pierre Martin-Hirsch
Marc Arbyn
References
[1] IARC Monograph Working Group, IARC Monographs on the
Evaluation of Carcinogenic Risks to Humans, vol. 90 of Human
Papillomaviruses, IARCPress, Lyon, France, 2007, Edited by V.
Cogliano, R. Baan, K. Straif, et al.
[ 2 ]M .A r b y n ,X .C a s t e l l s a g u ´ e, S. de Sanjos´ e et al., “Worldwide
burden of cervical cancer in 2008,” Annals of Oncology, vol. 22,
no. 12, pp. 2675–2686, 2011.
[3] M. Hakama, A. B. Miller, and N. E. Day, Screening for Cancer
of the Uterine Cervix: IARC Working Group on Cervical Cancer
Screening and the UICC Project Group on the Evaluation of
Screening Programmes for Cancer, vol. 76 of IARC Scientiﬁc
Publications, WHO, IARC, and UICC, Lyon, France, 1986.
[4] M. Quinn, P. Babb, J. Jones, and E. Allen, “Eﬀect of screening
on incidence of and mortality from cancer of cervix in
England: evaluation based on routinely collected statistics,”
British Medical Journal, vol. 318, no. 7188, pp. 904–908, 1999.
[5] G. Koliopoulos, M. Arbyn, P. Martin-Hirsch, M. Kyrgiou,
W. Prendiville, and E. Paraskevaidis, “Diagnostic accuracy of
human papillomavirus testing in primary cervical screening:
a systematic review and meta-analysis of non-randomized
studies,” Gynecologic Oncology, vol. 104, no. 1, pp. 232–246,
2007.
[ 6 ] M .A r b y n ,G .R o n c o ,C .J .L .M .M e i j e r ,a n dP .N a u c l e r ,“ T r i a l s
comparing cytology with human papillomavirus screening,”
The Lancet Oncology, vol. 10, no. 10, pp. 935–936, 2009.
[ 7 ]A .C .B a r c e l o s ,M .A .M i c h e l i n ,S .J .A d a d ,a n dE .F .M u r t a ,
“Atypical squamous cells of undetermined signiﬁcance: be-
thesda classiﬁcation and association with human papillo-
mavirus,” Infectious Diseases in Obstetrics and Gynecology, vol.
2011, Article ID 904674, 9 pages, 2011.
[8] D.Solomon,M.Schiﬀman,R.Tarone,andALTSStudyGroup,
“Comparisonofthreemanagementstrategiesforpatientswith
atypicalsquamouscellsofundeterminedsigniﬁcance:baseline
resultsfromarandomizedtrial,”JournaloftheNationalCancer
Institute, vol. 93, no. 4, pp. 293–299, 2001.
[9] A. Chranioti, E. Aga, N. Margari et al., “Performance eval-
uation of manual and automated (MagNA pure) nucleic
acid isolation in HPV detection and genotyping using roche
linear array HPV test,” Infectious Diseases in Obstetrics and
Gynecology, vol. 2011, Article ID 931281, 11 pages, 2011.
[10] G. Valasoulis, G. Koliopoulos, C. Founta et al., “Alterations in
human papillomavirus-related biomarkers after treatment of
cervical intraepithelial neoplasia,” Gynecologic Oncology, vol.
121, no. 1, pp. 43–48, 2011.
[11] M. Kyrgiou, G. Koliopoulos, P. Martin-Hirsch, M. Arbyn, W.
Prendiville, and E. Paraskevaidis, “Obstetric outcomes after
conservative treatment for intraepithelial or early invasive
cervical lesions: systematic review and meta-analysis,” The
Lancet, vol. 367, no. 9509, pp. 489–498, 2006.
[12] M. Arbyn, M. Kyrgiou, C. Simoens et al., “Peri-natal mortality
and other severe adverse pregnancy outcomes associated with
treatmentofcervicalintraepithelialneoplasia:ametaanalysis,”
British Medical Journal, vol. 337, pp. 1284–1296, 2008.
[13] K. McCaﬀe r y ,J .W a l l e r ,S .F o r r e s t ,L .C a d m a n ,A .S z a r e w s k i ,
and J. Wardle, “Testing positive for human papillomavirus in
routine cervical screening: examination of psychosocial im-
pact,” Journal of Obstetrics and Gynaecology, vol. 111, no. 12,
pp. 1437–1443, 2004.
[14] FUTURE II Study Group, “Quadrivalent vaccine against hu-
man papillomavirus to prevent high-grade cervical lesions,”
The New England Journal of Medicine, vol. 356, no. 19, pp.
1915–1927, 2007.
[15] J. Paavonen, P. Naud, J. Salmer´ on et al., “Eﬃcacy of hu-
man papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine
against cervical infection and precancer caused by oncogenic
HPV types (PATRICIA): ﬁnal analysis of a double-blind,
randomised study in young women,” The Lancet, vol. 374, no.
9686, pp. 301–314, 2009.